Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.
Description: Prevalence for anosmia in the COVID-19 + patients
Measure: Anosmia Time: 45 daysDescription: Prevalence for ageusia in the COVID-19 + patients
Measure: Ageusia Time: 45 daysDescription: Duration measured in days
Measure: Duration of the loss of anosmia ageusia Time: 45 days